# A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients

> **NCT00358150** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 26 (actual)

## Conditions studied

- Gaucher Disease, Type 1
- Cerebroside Lipidosis Syndrome
- Glucocerebrosidase Deficiency Disease
- Glucosylceramide Beta-Glucosidase Deficiency Disease
- Gaucher Disease, Non-Neuronopathic Form

## Interventions

- **DRUG:** Eliglustat tartrate

## Key facts

- **NCT ID:** NCT00358150
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2009-08
- **Final completion:** 2015-12
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358150, "A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00358150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*